Usuário:Valentia
De BISAWiki
Aortic aneurysms certainly are a prominent root cause of death worldwide, having boosting incidence along with epidemic. In the country, AAAs exist in nearly 5%-7% of the population over the age of 61 years old, often as an unknown disease. By having a substantial predisposition for rupture, AAAs are definitely the 15th main factor for loss of life over-all in america and also the 10th biggest source of dying in males over age FIFTY FIVE, with approximately 9, 000 AAA-related fatalities happening per year. EVAR for AAA symbolizes a good enhance in person care and attention, providing an appropriate option to standard open surgical AAA repair, and it is right now the most widespread treatment method intended for AAA fix in north america. Continuing technologic refinements have been produced for the reason that initial described EVAR in 1991. The revealed specialized and clinical positive aspects involving EVAR currently become similar or go over exactly the same outcome details regarding open surgical restoration. The method has triggered diminished operative periods, lessened intraoperative loss of blood and even transfusion specifications, minimized perioperative morbidity as well as fatality, in addition to lessened intensive care unit along with healthcare facility lengths of remain. Though these savings, alongside the better patient treatment period, may possibly lower the immediate fees regarding AAA repair, this unique primary monetary benefit could be balanced out via the costly ongoing followup imaging that is definitely suggested after EVAR. The Dutch Randomized Endovascular Aneurysm Management trial concluded that EVAR provides only a marginal entire survival profit, which is linked to a substantive, if not too high, financial impact boost. At the same time, however EVAR has been shown to reduce dying in addition to side-effect rates in the first thirty day period following the treatment compared to open repair, succeeding longer-term analysis of these randomized studies demonstrated a sustained benefit in terms of aneurysm-related mortality up to Four years, but the general survival distinction failed to persist beyond the initial 2 postoperative yrs. EVAR benefits usually are highly dependent upon proper affected person and also device selection; physician variables such as schooling, practical experience, and process volume; as well as a variety of institutional variables. EVAR operations can be extremely complicated and thus demand staff who have significant endovascular practical knowledge along with enhanced specialized skills. Effective outcomes additionally count on careful test of the applicable vascular body structure as well as suitable preprocedure preparing. Most of these guidelines are meant for use in assessing the standard of care and attention expected from just about all doctors who perform EVAR operations. The most important procedures of care are actually: 1. preprocedural imaging and planning 2. appropriate graft and patient selection 3. performance of the procedure 4. postprocedural surveillance 5. management of EVAR-related complications.
The result measures or indicators for these processes are signals, success rates, and complication rates, and are assigned threshold levels.
Abdominal Aortic Aneurysm is a everlasting pathological dilation of the abdominal aorta. Today, remedy is indicated when the diameter extends to 5.5 cm or is 2.5 times the ordinary aortic diameter or simply there is aneurysm development at a rate exceeding 1 centimeter each year. Restoration is always demanded regarding AAA rupture or simply if you have a symptomatic aneurysm (eg, back pain), which may be a sign of upcoming rupture. AAAs usually are categorised according to their particular anatomic relationship to the renal arteries, because this substantially affects treatment method. An infrarenal AAA has an intervening normal aortic segment (proximal neck) of at least 10 mm between the renal arteries and the most cephalad extent of the aneurysm, whereas a juxtarenal aneurysm extends to the renal artery level, with a normal-caliber aorta above. A suprarenal AAA not only involves the renal arteries, but extends cephalad so that the superior mesenteric artery and celiac artery arise from the aneurysmal aorta. AAAs may also extend distally beyond the aortic bifurcation to involve the common iliac arteries and occasionally the internal and/or external iliac arteries. A common iliac artery aneurysm has a diameter that reaches or exceeds 2 cm. Iliac artery involvement may significantly affect EVAR, as ancillary procedures may be necessary to ensure a successful outcome. AAAs may also be categorized by configuration: a fusiform AAA typically involves the entire circumference of an extended section of the aorta, and is a �true� aneurysm involving all three layers of the aortic wall. Saccular AAAs are more focal and localized and may be asymmetric or may occur as pseudoaneurysms that do not involve all mural layers.
INDICATIONS AND CONTRAINDICATIONS FOR EVAR In spite of advances in elective open surgical AAA restoration, there is still substantial connected morbidity and mortality. Exceptional benefits are usually reached in high-volume referral facilities but you may still find reported mortality rates up to 7% along with morbidity rates that approach 50 PERCENT in some centres. Even though open surgical restoration has been the standard of care for treating AAA, there are related well recognized negatives, including expanded surgical, anesthesia, and healing times, and also a potentially continuous hospitalization that involves use of the critical proper care unit. Aside from that many people are actually inadequately suited for open restoration as a result of coexisting medical ailments for instance cardiac, pulmonary, or renal dysfunction, which provide an increased operative and/or anesthesia threat, and thus unacceptably higher potential complication rates. Endovascular abdominal aortic aneurysm restoration has been utilized as a replacement treatment regarding affected individuals who're inappropriate pertaining to open restoration along with those that would be suitable for standard open surgical AAA restoration. A variety of healthcare trials have questioned the main benefit of EVAR in people having bad surgical danger and also have furthermore failed to definitely establish the actual sustained advantage along with durability of EVAR. Evidences for EVAR are currently similar to for open fix, although right now there are prolonged randomized prospective clinical trials which strive to evaluate if treatment using EVAR for smaller-diameter AAAs can be of great benefit. The not too long ago released results of the Positive Impact of Endovascular Options for Treating Aneurysms Early trial proved that early on remedy with EVAR and image-based monitoring, with aneurysm treatment as clinically pointed out, appear to be equally risk-free options for persons having small aneurysms of 4.0-5.0 cm in size. The research noted, howeve that the the desired info is based upon early details which may modify since longer-term information accrue. Sufferer suitability for EVAR is determined by several clinical as well as anatomic aspects. Anatomic variables may possibly directly affect the technical benefit and long lasting durability of EVAR, while medical aspects, just like medical comorbidities, influence morbidity and mortality (both early and late). Anatomic factors which have an impact on suitability for EVAR include adequacy of vascular access for device introduction; aneurysm morphology; neck length and morphology; and iliac artery involvement. Various series have suggested that there is substantial variability as to what percent of patients will certainly are eligible for EVAR, with regards to the criteria that are used to determine appropriateness.
Clinical variables impacting sufferer appropriateness for EVAR might be obtained based on healthcare comorbidities. There were different scientific studies revealing a low incidence of periprocedural problems along with EVAR compared to open operative AAA restoration. On the other hand, this has not really been affirmed in all scientific studies, since the Dutch Randomized Endovascular Aneurysm Management trial showed similar incidences involving cardiac additional complications for EVAR and open surgical AAA repair of 5.3% and 5.7%, correspondingly. Since cardiac fatalities represent the primary root cause of periprocedural and also delayed mortality pertaining to EVAR, an individual�s heart failure risk ought to be stratified ahead of remedy. Restricting preprocedural patient evaluation solely to heart failure danger fails to stratify for various other comorbid conditions that could furthermore in a big way impression outcomes. Thus, distinction systems have recently been established that make an effort to anticipate morbidity and mortality. All these rating systems include the age plus cardiac, pulmonary, and renal status of the patient and are meant to symbolize aspects which are prone to affect major morbidity and fatality linked to EVAR or open AAA repair. Preprocedurally, the clinical appropriateness of a affected person for EVAR really should be quantified just as much as probable, depending on virtually any health care comorbidities. Endovascular abdominal aortic aneurysm repair should be deemed as experiencing an intermediate to high cardiac associated risk that ranges from 3% to 7%. If preexisting cardiac ailment is recognized, correct involvement is highly recommended just before optional EVAR. Preexisting renal deficiency has a identified association together with negative EVAR final results. Renal status ought to be considered ahead of EVAR along with renal safety methods really should be used to handle any renal dysfunction.
Diabetes mellitus has been shown in the European Collaborators on Stent Graft Techniques for AAA Repair registry to be associated with a significantly higher risk of device-related complications and a higher early mortality rate. However, patients with insulin-controlled type 2 diabetes had lower rates of endoleaks and fewer secondary interventions than diet-controlled type 2 diabetic patients and nondiabetic patients.
Regarding patient age and AAA repair, one study has suggested that the mortality rate after open or endovascular AAA repair in carefully selected octogenarians seems acceptable but is higher than the mortality rate in younger patients, whereas another concluded that EVAR suitability is not influenced by age, aneurysm size, or patient fitness. Additionally, one single-center study cited significantly higher endoleak, open conversion, and renal infarction rates (P <.05) among a subgroup of patients older than 75 years, and also showed significantly elevated (P = .0011) aneurysm-related morbidity and mortality rates.
Patient selection for EVAR compared to open repair should be considered when appropriate; when informing people about the alternative, one can present figures from major trials. The midterm (4-year follow-up) results of the EVAR-1 trial highlighted a substantially decreased aneurysm-related death rate for affected individuals in the EVAR set: 4% compared with 7% for open repair. The reduced postoperative morbidity and mortality rates, the shorter clinic stay in, and the chance of usage of local or regional anesthesia may possibly benefit EVAR, but these must be balanced towards higher delayed unwanted effect in addition to repeat treatment rates along with the require for long-term monitoring.
Till not too long, there have been no aim studies substantiating whether there was an individual preference for EVAR. Having said that, an up to date research inspecting individual choices pertaining to elective potential AAA repair demonstrated 84% favored EVAR, 13% preferred open repair, and 3% weren't able to exhibit a preference. The outcomes of this research help support the general pattern towards providing EVAR in order to persons in whom it is technically prospective. Contraindications for EVAR generally are associated with anatomic or even medical variables that render the patient useless for this therapy. Very poor anatomic preprocedural individual selection is often linked to a the upper chances for complications and compromised extensive outcomes. In the same manner, sufferers at higher risk of having considerable perioperative or postoperative morbidity and fatality rate because of serious healthcare comorbidities could be weak applicants for any kind of AAA restoration. Options concerning EVAR opposed to open precise AAA repair ought to be made in concert along with other medical professionals involved in the patient�s treatment.
EVAR in Patients Requiring Urgent or Emergent Repair Recent studies of national trends in the United States have observed increasing use of EVAR in the emergency management of ruptured AAA, with decreasing mortality rates. Results in teaching and high-volume hospitals have been significantly superior to those in nonteaching and low-volume institutions. Achieving optimal EVAR results for ruptured AAA requires establishment of a treatment protocol involving the emergency department, the endovascular team, anesthesiology, and the operating room personnel. Hemodynamically stable patients in whom ruptured AAA is suspected should undergo emergency computed tomographic (CT) angiography, whereas those in unstable condition should be taken directly to the operating room, limiting fluid resuscitation to maintenance of patient consciousness and a systolic blood pressure of 70 mm Hg (ie, �hypotensive hemostasis�) to limit ongoing hemorrhage. Inflation of a compliant aortic occlusion balloon in a supraceliac or pararenal location may be useful in hemodynamically unstable patients or in anatomic situations that prevent expeditious EVAR. If a preprocedural CT angiography examination could not be obtained, determination of the aneurysm morphology, landing zones, and appropriate device must be based on intraoperative angiography. Endoprostheses used in emergency EVAR for ruptured AAA have included bifurcated and aortouniiliac devices. One must be vigilant for development of abdominal compartment syndrome in these patients. This well recognized complication after EVAR for ruptured AAAs occurs in hemodynamically unstable patients in whom a large retroperitoneal hematoma and diffuse visceral edema cause elevated intraabdominal pressure and multiorgan dysfunction. It is seen most frequently in patients requiring an aortic occlusion balloon, massive transfusion, or conversion to an aortouniiliac device, and in those with coagulopathy.
Optimal Endograft Type for Patient Anatomy Selection of an appropriate stent-graft for an individual patient is performed before the procedure after the accurate analysis of the diagnostic images. There are currently five FDA-approved devices available for use in the United States: The Zenith Flex AAA endovascular graft (Cook, Bloomington, Indiana) is a three-piece modular bifurcated graft made of woven polyester fabric with a self-expanding exoskeleton of modified Gianturco stainless-steel Z stents to provide support. The proximal end of the graft body has a series of 12 bare metal stents with caudally angled protruding barbs for suprarenal fixation to the aortic wall. The stainless-steel composition of the stents render this device incompatible with MR for post-procedural surveillance. Zenith endograft diameters range between 22 mm and 36 mm for the proximal component and from 8 mm to 24 mm for the iliac limbs. There are also proximal aortic body extensions, as well as proximal aortic converter cuffs that are designed for conversion of the bifurcated graft design to an aortouni-iliac configuration. Conversion to this latter configuration also requires the use of an available iliac plug. The Flexor delivery system uses a flexible, kink-resistant sheath that ranges from 18 F to 22 F in inner diameter and has a hydrophilic coating to facilitate device introduction. Because of the available large aortic component diameters, this graft is indicated for implantation in AAAs with neck diameters as large as 32 mm and lengths that are greater than 10 mm; the neck angulation should be less than 60�. The Powerlink AAA endovascular graft (Endologix, Irvine, California) is a unibody bifurcated design graft that is made of expanded polytetrafluoro-ethylene that is attached to a self-expanding cobalt/chromium endoskeleton. The tubular component of the unibody graft is available in 25- and 28-mm diameters; the iliac limb components have a distal diameter of 16 mm. There are tubular and flared iliac limb extensions available. Proximal tubular aortic extensions are available without suprarenal fixation or with a 20-mm-long bare metal suprarenal fixation design. This unibody design device is positioned so the graft bifurcation is placed at the aortic bifurcation to prevent any caudal migration. The aortic extension is then introduced and positioned with the proximal fabric-covered end immediately below the most inferiorly located renal artery origin. Because of the unibody graft design, cannulation and contralateral placement is unnecessary. The IntuiT-rak introducer system employs a 19-F inner body hydrophilic delivery sheath. Placement of a contralateral 9-F sheath is required to allow for positioning of the contralateral iliac component. This smaller diameter requirement for the contralateral limb allows for percutaneous access and may be advantageous if there is a unilaterally small caliber or diseased access vessel. The Excluder AAA endoprosthesis (W.L. Gore and Associates, Flagstaff, Arizona) is a two-piece modular device consisting of a main-body ipsilat-eral limb and a contralateral limb, both constructed with a self-expanding nitinol stent skeleton lined by expanded polytetrafluoroethylene. The original fabric of this graft had porosity issues that resulted in high rates of post-EVAR residual AAA sac expansion, but this problem has resolved since replacement of the original fabric. The graft main body is designed for infra-renal fixation, with a series of small proximal fixation anchors or �whiskers� designed to imbed within the arterial wall at the proximal attachment site and impede caudal graft migration. The Excluder AAA endoprosthesis body ipsilateral limb component is available in diameters of 23 mm, 26 mm, 28.5 mm, and 31 mm, with aortic extender cuffs available. The contralateral iliac docking limb component has available tapered, straight, and flared configurations. The device is delivered through 20- 24-F sheaths and is deployed via the sheathless Sim-pull system.
PROCEDURE: TECHNICAL ASPECTS Anesthesia Traditionally, EVAR is performed under regional or general anesthesia. As mortality, postoperative complications, and length of stay are the consequences of surgical and anesthetic techniques, a change in the latter may contribute to reduce morbidity and costs after EVAR. Feasibility and small cohort studies have reported encouraging results with the use of locoregional anesthesia for EVAR. Other authors, however, found no difference in cardiac mortality and morbidity in a retrospective cohort of patients receiving locoregional anesthesia or general anesthesia. There is no level I evidence for or against locoregional anesthesia in EVAR, as there are no randomized controlled trials or large prospective studies documenting its role in EVAR. However, the European Collaborators on Stent Graft Techniques for AAA Repair data indicate that patients appeared to benefit when locoregional anesthesia was used for EVAR and suggest that these techniques should be used more often to enhance the perioperative advantage of EVAR. Additionally, a recent review of selected studies showed that, although patients undergoing locoregional anesthesia were less medically fit compared with those in the general anesthesia group, there were reductions in the cardiovascular support required during and after surgery, postoperative hospital stay, intensive care unit stay, and postoperative mortality and morbidity. Choice of anesthesia must be tailored to the individual patient, and will typically vary by operator and by institution.
Intraprocedural Imaging Endovascular abdominal aortic aneurysm repair should be performed in an operating room or an angiography suite with a sterile configuration, a radiolucent operating table, and all necessary equipment should surgical conversion be required. State-of-the-art imaging equipment with a stationary fluoroscopy machine or dedicated new-generation C-arm should be used. As procedure times and potential radiation doses to the operators and the patient may be substantial, imaging equipment should be equipped with dose reduction technology such as variable-rate pulsed fluoroscopy. The operator should be familiar with dose reduction strategies such as collimation, appropriate x-ray tube-to-patient distance, and avoidance of redundant views. If a C-arm is used intraprocedurally, one must be aware of the potential for delays that may occur during prolonged equipment use, as a result of the accumulation of heat energy that may limit x-ray production if insufficient cooling is allowed. There is also more rapid heat energy accumulation in patients with large body habitus and with use of magnification fluoroscopy. Appropriate use of pulsed fluoroscopy, collimation, and limitation of magnification and steep angulation may prevent delays from excessive x-ray tube heat loading. Thorough knowledge of appropriate geometric adjustments of the imaging equipment relative to the vascular anatomy is essential for optimal outcomes. Parallax correction, as well as the appropriate use of oblique projections to optimally display the origins of vessels such the renal or internal iliac arteries, for example, is required to insure appropriate placement of the graft components at the landing zones. Some investigators have advocated routinely use of intravascular US during EVAR. Intravascular US use during EVAR requires complete familiarity with this technology in target site and branch vessel identification, landing zone measurement, neck analysis, and intraprocedural troubleshooting. Intra-vascular US may be beneficial in patients with excessive abdominal girth in whom intraoperative fluoroscopy and angiographic imaging do not provide adequate imaging for procedural precision during EVAR. Although the routine use of intravascular US might minimize renal contrast medium exposure, as well as reduce radiation exposure, in most centers intravascular US has an ancillary role, when and if it is used, and is not currently considered the standard of care. There has been debate as to whether certain iodinated contrast agents may pose less risk of CIN than others. A recent metaanalysis of randomized controlled trials comparing the nephrotoxicity of isoosmolar iodixanol with nonionic low-osmolar contrast media concluded that there is no significant reduction in the relative risk of CIN with the use of iodixanol compared with nonionic low-osmolar contrast media pooled together. In patients with renal insufficiency who require intraarterial administration of contrast medium, iohexol is associated with a greater risk of CIN than is io-dixanol, whereas there is no significant difference in the relative risk of CIN between iodixanol and the other nonionic low-osmolar contrast media in patients at high risk. Thus, iodixa-nol or a nonionic low-osmolar contrast agent other than iohexol may be used in patients at risk for CIN.
POSTOPERATIVE MANAGEMENT Following an uncomplicated EVAR procedure, the patient is admitted for overnight observation, with appropriate analgesia for pain management, continuation of intravenous fluids as necessary, evaluation of appropriate dietary intake, and monitoring of the access sites, cardiopulmonary status, ambulation ability, and overall general postoperative state. Complicated procedures may require the administration of blood products, a potentially lengthier hospital stay that may include intensive care, and early postoperative evaluation with CT. Unfortunately, there is a lack of prospective randomized trials concerning the medical management of patients who have undergone EVAR. Treatment is in line with the medical management of coronary artery disease including antiplatelet therapy and statins. Antiplatelet therapy may prevent complications such as graft-limb thrombosis and peripheral arterial disease. Especially in patients with PAD, aspirin, clopidogrel, and statins remain mainstays of medical management.
